Introduction
Water-in-oil-in-oil (W/O 1 /O 2 )e mulsion hasbeen proposed toenhancethe enteralbioavailability of drugs,including peptides [1] [2] [3] .Ano rali nsulin (CAS 9004-10-8) administration could haveanadvantage byachieving portali nsulin delivery in ac onvenientw ay.The developmentof ano rald osage formp roviding adequate bioavailability of insulin would revolutionizethe treatmentof diabetes.The problemsencountered witho ral dosage formsof insulin arerapid enzymaticdegradation in the gastrointestinaltractand poormembrane permeability.Ino rdert od evelop ano rali nsulin dosage form, itisnecessary thatt hesee nzymesbei nhibited. Recent studieshaveshownthats ome proteasei nhibitors amplifythe biologicaleffectof insulin injected directlyinto the lumen of the intestine [4] [5] [6] .Thesestudiess uggested thatitwasfeasible toabsorbinsulin from the intestine in the presenceo fthe proteasei nhibitor.The emulsion hasadvantagesforenteralp eptidesdelivery becausei tprotects peptidesagainst proteolysis [1, 3] and enhancest he absorption of normallynon-absorbed waters oluble substances [1] [2] [3] .Further,multiple emulsionsaree asy toh andle and drink duetotheirlowv iscosity.Thus,therei sapossibility fordeveloping ano ral dosage formofinsulin byusing the emulsion. The most convenientadministration routeo fi nsulin forpatients would beaperorali ngestion of asuitable dosage form. The advantagesoffered bymultiple emulsionsascarriers of drugsfororaladministration include protection against enzymatichydrolysisand enhanced absorption
Abstract
The aim of thiss tudyw ast oi nvestigate the applicability of microspherescontaining proteasei nhibitorfororald elivery of insulin (CAS 9004-10-8). Microspheresof insulin wereprepared by water-in-oil-in-oil (w/o 1 /o 2 )d ouble emulsion solventevaporation method. Formulationswithd ifferentdrug/polymerr atiosw erep repared and characterized bydrugl oading,loading efficiency, yield,particle size,scanning electron microscopy(SEM),F ourierTransform Infrared spectroscopy(FTIR). The in vitro releasestudiesw ereperformed in pH1.2 and 7.4. Invivo studieson rats wereconducted in ordert oi nvestigatethe bioavailability and performanceofo ralm icrospheres.The best polymert od rug ratio in microsphereswas15.6:1( F 2 formulation). The loading efficiencyw as 77.36 %,productionyield was54.55 % and meanp article sizewas2 22.4 µm. SEM studiess howed thatt he microspheresw eresphericaland porous in nature. Dataobtainedfrom in vitro releasewerefitted tovarious kineticmodels and high correlation wasobtainedin the first ordermodel. The results of enzymaticdegradation indicated thatinsulin could bep rotected from trypsinic degradationinthe microspheres.Our results indicatethatthe microspherescontaining aprotinin (CAS 9087-70-1) have the advantage of high loading efficiency, pHresponsiveand prolonged releasecarrying insulin tothe optimumsiteo fabsorption asw ell ast he enhanced insulin absorption and biologicalresponse.
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n Double-emulsion solvent diffusion n Enzymaticdegradation n Insulin n Microspheres n Orald elivery n Proteasei nhibitor through the intestinalwall. One of the strategiesof oral insulin delivery isu sage of enzyme-inhibiting agents. Enzyme inhibiting agents arebecoming increasingly popularasadelivery strategyfororali nsulin. Insulin, like manyotherprotein and peptide drugs,isdegraded in the gastrointestinaltract(GIT)bydigestivee nzymes suchaspepsin,proteases,peptidases,and otherproteolyticenzymes.The propers election of proteasei nhibitors dependson boththe peptide and protein drugto bed elivered and on the type of proteasesand peptidasesu sed top rotectt he drugi nthe GIT.Furtherattempts toi ncreasethe hypoglycemiclevelsin diabetic animalsw erem ade byintroducing enzyme inhibitors and proteasei nhibitors (aprotinin (CAS 9087-70-1) or the Bowman-Birki nhibitor)top reventt he degradation of insulin in the intestine bypancreaticenzymes [7, 8] .
Ino ne study,the useo fatrypsin inhibitorcaused greaterhypoglycemiceffectin agelatin microspheres formulation containing insulin [9] .Ithasbeen suggested thataprotinin orbacitracin (proteasei nhibitors) maycauseasignificantand prolonged plasmaglucose reduction in diabeticrats [10] .Morishita etal .used microspheresforinsulin delivery in rats [11] .Theirs tudy showed thatmicrospherescarrying insulin and aprotinin enhanced insulin absorption. The results from in situ closed small and large intestinall oopsin rats suggest thatproteasei nhibitors could increasei nsulin absorption moree ffectivelyin the large intestine thani n the small intestine [7] .Side effects suchass ystemicintoxication and disturbed digestion of food proteinsare regularlyassociated withthe useofinsulin withenzyme inhibitors [12] .Aprotinin ismostlyu sed in extensive cardiac surgery and liverbyintravenous injection. Aprotinin hasfews ide effects but mayoccasionallycause allergic/anaphylacticreactions [13] .Theseside effects havep rompted caution in the useo fe nzyme inhibitors in orali nsulin formulations.The abovem entioned side effects canbereversed,however,if oralinsulin formulationsared esigned tocontain ani nhibitort hatr eleases insulin and ani nhibiting agentatt he same time and limitits action toac ertain areawithin the intestine.
Insitu intestinale xperiments on rats indicatethata water-in-oil-in-wateremulsion containing docosahexaenoica cid mayimprovei nsulin absorption without causing anys erious damage tothe intestinale pithelial cells [12] .Agroupo fresearchers developed astrategy tousebothanabsorption promoter(sodiuml aurylsulfate) and ane nzyme inhibitor(aprotinin) separatelyin theirformulation and reported areduction in blood glucosel evelsin beagle dogs [14] .The process produced insulin loaded polymericmicrospheresw ithd esirable releasecharacteristicss uchaslowinitialburst,narrow particle sized istribution,high loading,a nd preserved integrity of the encapsulated protein.
Inthiswork,microspherescontaining proteaseinhibitors asenteralcarriers of insulin werep repared with the intention of enhanced intestinalabsorption of insulin. The physicochemicalp ropertiesof microspheres, hypoglycemiceffectof microspheresaswell asbioavailability of insulin from the microspheresin rabbits were investigated.
2.Materialand methods

Materials
Recombinantinsulin wasobtained from E.coli (28.3U/mg,E li Lilly,I ndianapolis,I N, USA). Aprotinin (Sigma-Aldrich,S t. Louis,M O, USA),E udragitS100 (Röhm Pharma, Weiterstadt, Germany),ethylalcohol,hydrochloricacid,liquid paraffin,gelatin,sodiumchloride,potassiumchloride,phosphatebuffer saline (pH7.4). Trypsin (Gibco,O ntario,C anada),pepsin and streptozocin (Sigma-Aldrich),methylcellulose( Shin-Etsu,T okyo,J apan),I nsulin Isophane (NPH, ExirCompany,B oroujerd, Iran),glucoseand insulin EIA kit(Diaplus Co.,S anFrancisco, CA, USA).
2.2Experimentalm ethods
Microsphereswereprepared byusing water-in oil-in oil (W/O 1 / O 2 double emulsion solventdiffusion method) using different ratiosof insulin (withorwithout proteaseinhibitor)toEudragit S100 ratios(1 :7.8,1:15.6,1:31.2,1:62.4 and 1:124.8 asshown in Table 1 ). EudragitS100 (500 mg) wasdissolved in 5mlo f ethanol. The initialw/oe mulsion wasprepared byadding 300 l lo f0.1 NH Clcontaining insulin (32 mg) witho rw ithout proteasei nhibitor(aprotinin) tothisethanolicpolymers olution while stirring at500 rpm. Thisw /op rimary emulsion was slowlyadded to50ml of lightliquid paraffin,while stirring bya paddle propellerat1200 rpm,immersed in ani cewaterbath. After2h,50ml of gelatin solution (0.5 %w/w)wasadded to harden the microspheresand stirring wascontinued fora further1h and the hardened microspheresw erecollected by filtration and washed withthree portionsof 50ml of n-hexane and then freeze-dried [8,15 -17] . 
2.3Determination of drugcontentof microspheres
Drugamountin microspheresw asdetermined bydissolving 10mg of eachsample in 10ml of the mixed solvents ystem consisting of ethanol and saline phosphatebuffer(pH7.4) in 1:1ratio. The drugconcentrationwasdetermined spectrophotometrically(UV-160,S himadzu,K yoto,J apan) at2 76 nm. The productionyield of the microsphereswasdetermined bycalculating accuratelyt he initialweightof the rawmaterialsand the last weightof the microspheresobtained [16] [17] [18] .All of the experiments werep erformedi ntriplicateand the meano fthe valueswasr eported.
Scanning electron microscopy(SEM)
The morphologyof microspheresw asexamined withascanning electron microscope (LEO 440i,C ambridge,E ngland)o perating at15 kV.The samplesw erem ounted on ametalstub withd ouble adhesivetape and coated withp latinum/palladiumalloyundervacuum.
Fourier-TransformInfrared spectroscopy(FTIR)
The infrared spectrumo fthe drug,microspherescontaining the drugwereo btained in potassiumbromide discs(0.5 %w/ w)using aF TIR (Bomen,Q uebec, Canada)spectrophotometer [19 -23] .
2.6Fouriers elf deconvolution (FSD)
Fouriers elf deconvolution isamethod of computationallyr esolving overlapping linest hatcannotbei nstrumentallyr esolved duetotheirintrinsiclinewidth. Thiscanbeusefulf or moreaccuratedeterminationofthe numberof peaksin atrace region,the band positions,a nd areas.Thist echniquecanbe used toaccuratelydeterminestarting parameters forapplicationssuchascurvefit.Thisapplication isbased on the method described byGriffithsand Pariente [24, 25] .Twof ilters areemployed in thismethod. Ane xponentialf ilterisu sed tosharpen spectralf eatures; the constant g isv aried tochange the filter shape. The g parameterequalst he full widthathalf height (FWHH)ofthe widest resolved peak. Realizethatt he filters are boxcareand Bessel,a nd arem athematicallydescribed below. The deconvolution filterisasimple exponentialf ilterof the forme 2 pgX where g isdeconvolution filterconstantand Xist he array(i. e. datafile) whoseXrange isnormalized between 0and 1. Thisfunction ismultiplied byt he Fouriert ransformedtrace, and the dataisthen reverseFouriertransformedtogivethe result[24-25].
2.7Circulardichroismspectrophotometry
Circulardichroism( CD)spectroscopyisr emarkablys ensitive tothe secondary structureofbiologicalp olymers.The effectof encapsulation on the conformationo fi nsulin wasevaluated withCD spectrophotometery.The samplesforCD analysis wereprepared asfollows:
(1) Insulin alone wasdissolved in HCL solution (pH2.5),asa standardcontrol.
(2)Lyophilized insulin microspheresw ered issolved in 0.1 mol/LN aOH solution. The resultants olution then centrifuged at12000 revolutionsperminutef or3 0min. The supernatantw ascollected and the concentrationo fi nsulin adjusted using deionized waterast he sample.
Inthe abovesolutions,the finalconcentration of insulin was 0.2mg/ml foreachand confirmed using aU Vspectrometerat 276 nm. The control solutionsors ample solutionsw erem easured using aC Dspectrophotometer(JascoJ-810,T okyo,J apan). The measurementconditionsw ereasfollows:temperature,20°C;a0.2-cmcuvette;w avelengthrange,200 -250nm; resolution,2nm;and scanningspeed,200 nm/min witha1s responsetime. Noisereduction,b lank buffers ubtraction,a nd dataa nalysisw erep erformed using astandardanalysisand temperature/wavelengthanalysisprogram [26] .
Particle sizeanalysis
Alaserlights cattering particle sizeanalyzer(SALD-2101,S himadzu,K yoto,J apan) wasu sed tod eterminethe particle size of the drugand microparticulatef ormulations.Samplesof freeze-driedm icrospheresw ered ispersed in 2-methylp ropane-1-ol (iso-butyl-alcohol) aftert reatmentin anultrasonic disperserfor5min tobring about disaggregation of the microspheres [27] .
Invitro releasestudy
Dissolution studiesw erecarried out using aU SP basketmethod at37°Cand 150rpm. 200 ml of 0.1 NHCl(with1mg methyl cellulosetop reventadsorption tothe vessel glass)weree quilibrated at3 7±0.5°C.Microspheres(100 mg drug) werep laced in the apparatusand 4mlaliquots of mediumwerewithdrawn atpre-sett imesover2hand replaced by4mlo ff reshm edium. The samplesw eref iltered through 0.45 l mf ilters and used fort he spectroscopicdeterminationo fthe drug. Dilution withthe same buffersolution wascarried out if necessary.After 2h,the basketwaswashed withpurified waterand replaced in the same beakercontaining 200 ml of saline phosphatebuffer (pH7.4) at37°Cwithconstantstirring at100 rpm [8] .Atappropriatei nterval,4mlsamplesw eretaken from the mediumand filtered. Drugconcentration in the samplesw asmeasured by UV spectrophotometrica nalysisat2 76 nm foracidica nd entericbuffers.Eachexperimentw asr epeated three times [8] .
2.10Enzymaticdegradation study
Pepsin degradationwasdone forall microspheref ormulations. A100 mg sample of the microspheresw asincubated for1hat 37°Cwithreciprocalshaking (50strokes/min)i n1 0ml of pepsin solution (weightr atio of insulin toe nzyme,200 :1;glycine buffer,pH1.3). The microspheresw erethen collected byfiltration and washed withp urified water.The collected microspheresw erethen placed in 10ml of phosphatebuffer (pH7.8) and dissolved completely.Similarly,incubation with non-incorporated insulin wasconducted undert he same experimentalconditions [8] .
Forthe trypsinicdegradationstudy,the respectiveenzymatic solutions(weightr atio of insulin toe nzyme,1:0.5,1:1,1:2; phosphatebuffer,pH7.8) wereused. A20 mg sample of microspherescontaining aprotinin wasincubated for3hat37°Cwith reciprocalshaking(90strokes/min) in 5mloftrypsin solution [8] .
Forcontrol experiments,a ll preparationsw erei ncubated in enzyme-free solution undert he same conditions.The protectivee fficiencyof the preparationtowardsenzymaticdegradation wasexpressed asthe relativepercentage of the residualinsulin amountt othe control. Determination of insulin was performedbyane nzyme immunoassay(EIA)using the insulin EIA kit [8] .
Invivo studies
Adultmale Wistarr ats wereo btained from the AnimalCentre of the localUniversity,T abriz,I ran. Theyw ereh oused in air-
Antidiabetics
Arzneimittelforschung 2011;61(1): [14] [15] [16] [17] [18] [19] [20] [21] [22] conditioned quarters underaphotoperiod schedule of 12h light/12hd ark. Theyr eceived standardl aboratory dietand tap water,a vailable atlibitum .Wistarr ats of male sex,weighing 250±10g,wereselected. Diabetesw asinduced in rats byan injection of streptozocin (70 mg/kg). Rats wereconsidered diabeticwhen glycemiawashigherthan300 mg/dl one week after streptozocin administration. Rats weref asted over12hbefore starting the test and wered ivided into8groupsof 10animals. Inall of experiments,adoseo fi nsulin (20 IU/kg bodyw eight) wasadministered bys ubcutaneous injection ort he oralroute. Insulin microspheresw ithand without aprotinin wasadministered viagavageswithafeederneedle intothe stomachofnormaland diabeticrats in phosphatebuffer.Blood samplesw ere collected from the tail vein;blood glucosel evel wasmeasured beforei njection and 0.5,1,2,4,6and 8h post injection using aglucometer(Roche diagnostics,G ermany). Serumwass eparated bycentrifugation at3 000 rpm for3min and keptfrozen until analysis [28] .The absorption of intactbiologicallyactive insulin wasevaluated bymeasuringthe hypoglycemiceffect. The areasu ndert he curves(AUC)o fthe glucoseconcentration-time profilesw erecalculated withthe lineart rapezoidal method. Serumglucoselevelsafterinsulin administration were expressed asapercentage of the initiall evel. The cumulative percentage of change in serumg lucosel evel wascalculated by summing the areasbelowbaseline levels(negativevalues) using the trapezoidalm ethod. The relativebioavailability was calculated bythe ratio of the respectiveAUC of oraltosubcutaneous administrations [27, 29] .Approvalf ort he studyw asobtained from the localresearche thicscommittee (TabrizUniversity of MedicalSciences,T abriz,I ran) in advance. Inall animalstudies"Guide tothe careand useofe xperimentalanimals"byt he CanadianCouncil on AnimalCare,wasfollowed [30] .
3.Results and discussion
The effectof drug/polymerr atio on the physical propertiesof microspheres
Microspheresw erep repared byt he emulsion-solvent evaporation (ESE)method using differentdrug-polymer ratios(1 :7.8,1:15.6,1:31.2,1:62.4 and 1:124.8). The drugl oading wasatt he range of 53.36 %and 108.68% (Table 2) .
AnSEM photograph of microspheres(F 2 )i ss howni n Fig. 1 . The surfaceo fm icrospheresappeared spherical. The loading of the drugd epended on the solubility of the drugi nthe solventand continuous phase. Insulin loading percentage using EudragitS100 asmatrixmaterialsw ere77.36 %f orF 2 microspheresw ith1 :15.6r atio significantly(p <0.05).
Microspheresin the sizerange 209-377.93 l mwere obtained ( Table 2) . Itisclearfrom Table 2 ,generally,a s the polymeramountincreased,particle sizewasincreased. The drug/polymerr atio affected the particle sizef orinsulin microspheres.
FTIR patternsof insulin powders,polymerS100,physicalm ixtureo fF 2 ,lyophilized insulin microspheresare illustrated in Fig. 2A . .Afterinsulin hadbeen encapsulated intothe microspheres,the characteristicpeaksforinsulin werecovered byt he strongerintensity peaksof matrixmaterials [26] .On the otherhand,the C=Ostretching bandsof Eudragit S100 in microspheres(at1731cm Table 2 :E ffectof differentdrug/polymerratio on the drugcontent,productionyield,and particle sizeofinsulin microspheres.
Formulation
Drug:polymer ratio insulin and EudragitS100 takesplaceduring encapsulation.
Conformation of insulin inside microspheresw as evaluated using circulardichroismspectrophotometery (Fig. 2C) . The circulardichroismspectrumo fstandard insulin showed ellipticity troughsat208and 222 nm,respectively.The circulardichroismspectrumo fi nsulin microspheresdemonstrated thatt he matrixmaterials and/orformulation procedurei nfluenced insulin conformation [3, [7] [8] .
The parameters of the secondary structureo fi nsulin conformation (i. e. a -helix, b -sheet, b -turn,a nd random coil) areshowni nTable 3.When compared withthe conformation parameters of intactinsulin,encapsulation withEudragitS100 microspheres(F 2 )o bviously altered the secondary structureo fi nsulin asfollows: ahelixdecreased by11.7%, b -sheetdecreased by1.1 %, bturni ncreased by4.6%and random coil increased by 8.2%,respectively (Table 3) .
Therewasaremarkable decreasei n a -helixconformation,a ccompanied byequivalentincreasei nunordered structuresin the microspheres.Newpeaksat 1662.77 and 1737.16cm -1 emerged in microspheres, whichcould beassigned torandom conformation. This contributed tothe increasei nunordered structures. Random peakwasindicated byFTIR, FSD and CD analysisin all the microspheres,though the peakwas too small toappearin the second derivativespectra.A majorincreasei nunordered structurecame from increaseinturnconformation. Thereforethe observations indicatethatt he formulation process affects the a -helix conformationsof the insulin resulting in ac onformationaltransition torandom and turnstructures, b -sheet structuresmostlyr emaining unchanged. The helixt o random coil transition isathoroughlys tudied phenomenon. Thist ransition isvery abruptand canoccur upon change of temperature,solventetc. [31] [32] [33] .
Invitro releasestudies
The releaseprofilesof insulin from microspheresof differentdrug/polymerr atio areshowni nFig. 3.Burst releaseofinsulin from microsphereformulationswaslow. When microspheresarep repared bydouble-emulsion (W/O 1 /O 2 )m ethod,water-soluble drugsdo nothavea tendencyt om igratetothe organicmedium,thereby concentrating att he surfaceo fthe particlesand the resulting burst effectw ill bel ow [34] .Moreover,the burst releasecould alsobee xplained byt he imperfectencapsulation of the drugi nside microspheresw hereasdecreased burst releasemaybeattributed tothe increased thickness of the polymerlayers urrounding the drug. Similarbehaviorw asobserved in verapamil prepared withEudragitRS100 [14] .Inm ost cases,abiphasicdissolution profile wasobserved atpH1.2:the initialrapid drugl eakage generallyended very early(within first 120 min aftert he change of dissolution mediump Hto 7.4);fort he remaining time,nearlylinearbehaviorw as observed. Itisassumed thatt he first portion of the curvesisduetoi nsulin dissolution,whichstarts immediatelyaftert he beginning of the test fort he portion of drugonthe surfaceofmicrospheres.Aftersuchaphase, twophenomenacancombine in enhancing in the diffusion of the remaining dispersed drugi ntothe bulk phaseasw ell ast he formation of poresw ithin the matrixduetothe initiald rugd issolution;particle wetting and swelling whiche nhancest he permeability of polymert othe drug [26] (Fig. 3) . The releaserateatpH7.4 wasfastert hanatpH1.2.Comparing the drugrelease from microspheress hows thatt he drugreleased uring bothg astrica nd entericstagesforformulationsF 1 and F 2 washigherthanf orotherformulations(p <0.05).
Model independentanalysisof datawasperformed by comparison of DE (dissolution efficiency),t 50% (dissolution time for50%release) and similarity factor (Table 4 ) [35] .The DE wascalculated from the areaunderthe dissolution curveatt ime ti(measured using the trapezoidalrule) and expressed aspercentage of the areaof the rectangle described by100 %d issolution in the same time [16,23,28,36 -39] .Among the formulationsinsulin microspheresw ith1 :7.8 drug/polymerr atioss howed the highest dissolution efficiency,39.29. Releasep rofile of formulation F 2 wass imilart othoseo fF 1 tensivelyfort he parametricrepresentation of dissolution data [ 14, 31, 38] .The fitparameters toHiguchi, first-order,P eppasand zero-orderequationsarep resented in Table 5 . Applying first orderkinetics,ahigh correlation coefficientw asobserved fort he releasep rofile of all formulations.The dataobtained werealsop ut in the Korsemeyer-Peppasmodel in ordert of ind out the nvalue,whichd escribest he drugreleasem echanism. The nvalueo fm icrospheresof differentdrug/ polymerratio wasbetween 0.4173 -6052,indicating that the mechanismo fthe drugreleasewasdiffusion and erosion controlled (Table 5 ) [38] .
3.3Enzymaticdegradation studies
The results of pepsinica nd trypsinicdegradation studiesareshowni nFig. 4. Insulin solution wasdegraded during incubation in pepsin solution. However,aconsiderable amountof insulin remained unchanged in microspheresaftert he acidicincubation of F 2 withand without aprotinin (71.91 %and 70.87%,respectively) (Fig. 4A) . Aftert rypsinicincubation,c ompletei nsulin degradation wasobserved forinsulin solution in the absenceo fp roteasei nhibitor.The amountof insulin remaining aftert he trypsinicincubation of formulation F 2 withand without aprotinin was7 6.95 %and 70.87%, respectively (Fig. 4B) .
Relativebioavailability and hypoglycemiceffectof orali nsulin microspheresin diabeticrats
Average serumg lucosel evel vs time profilesafteradministration of subcutaneous (s.c.) insulin solution and oralm icrospheres(F 2 )tod iabeticrats areshowni n Fig. 5 . Following s.c.administration,the serumg lucosel evelsw erel owert hanthe initiall evel and thatof orallyadministered microspheres.The profilesof serumg lucosel evelsaftert he administration of microspheresw ithand without aprotinin weren earlys imilar (p >0.05). Incomparison tocontrol grouporaladministration of microspheresdecreased serumg lucosel evel (Fig. 5) .
However,the fall in blood glucosem ayinducethe releaseo fcounterr egulatory hormoness uchasglucagon, growthh ormone and cortisol [7, 40] .Inp articular,glucagon plays amajorr ole in the recovery from hypoglycemiain the normalstate. However,thisphenomenon mightnotoccur in diabeticrats.Onthe otherhand, the marked change in serumg lucosel evelsobserved in diabeticrats maybeattributed tothe absenceo fthese phenomena [ 7] .
The relativee fficacyof F 2 microspheresw ithand without aprotinin in comparison tos.c.administration todiabeticrats,the percentagesof change in serumglucosel evelsared emonstrated in Fig. 5 . The results indicated thatt he hypoglycemiceffectof insulin microspherescontaining aprotinin wass lightlymorethan thatof microspheresw ithout aprotinin (oraltos.c.administration efficacyr atio of %2.98 and %2.72,respectively)although the differencewasnots tatisticallys ignificant(p >0.05). Thiscould bep artlyascribed tothe factt hataprotinin maybed estroyed byorali ntake. 
Conclusion
Insulin-EudragitS100 microspheresw erep repared using double emulsion (w/o 1 /o 2 )solventdiffusion method. The drug:polymerr atio influenced the sphericity of the microspheres.The entrapmentefficiencywas high forall formulations.Insulin releasef rom the microspheresfollowed the first orderkineticmodel controlled bydiffusion and erosion mechanism. The results indicatethatthe process of microsphereformation isaffecting the a-helixconformationsof insulin resulting in ac onformationaltransition torandom and turnstructures, b -sheets tructuresmostlyr emaining unchanged. The results of enzymaticdegradation showed thatr egardless of the existenceo faprotinin inside microspherest he encapsulation of insulin inside Eudragit S100 microspheresprotects insulin from pepsinica nd trypsinicdegradation. The findingsof in vivo experiments demonstrated ane nhanced hypoglycemiceffect of insulin following oraladministration of insulin microspheres; however,thishypoglycemiceffectisnotsignificantlydependenton the existenceofproteaseinhibitorinside the microsphere.
